IL311984A - תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש - Google Patents

תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש

Info

Publication number: IL311984A
Authority: IL; Israel
Prior art keywords: methods; ion channels; gated ion; modified ligand; ligand
Prior art date: 2016-07-07

Application number

IL311984A

Other languages

English (en)

Original Assignee

Hughes Howard Med Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-07-07

Filing date

2017-07-07

Publication date

2024-06-01

2017-07-07 Application filed by Hughes Howard Med Inst filed Critical Hughes Howard Med Inst

2024-06-01 Publication of IL311984A publication Critical patent/IL311984A/he

Links

108090000543 Ligand-Gated Ion Channels Proteins 0.000 title 1
102000004086 Ligand-Gated Ion Channels Human genes 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Immunology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Toxicology (AREA)
Neurology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Marine Sciences & Fisheries (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Diabetes (AREA)

IL311984A 2016-07-07 2017-07-07 תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש IL311984A (he)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662359534P	2016-07-07	2016-07-07
US201762486779P	2017-04-18	2017-04-18
PCT/US2017/041147 WO2018009832A1 (en)	2016-07-07	2017-07-07	Modified ligand-gated ion channels and methods of use

Publications (1)

Publication Number	Publication Date
IL311984A true IL311984A (he)	2024-06-01

Family

ID=60892565

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
IL311984A IL311984A (he)	2016-07-07	2017-07-07	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש
IL304040A IL304040B2 (he)	2016-07-07	2017-07-07	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש
IL264098A IL264098B2 (he)	2016-07-07	2017-07-07	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
IL304040A IL304040B2 (he)	2016-07-07	2017-07-07	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש
IL264098A IL264098B2 (he)	2016-07-07	2017-07-07	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש

Country Status (12)

Country	Link
US (6)	US11084853B2 (he)
EP (1)	EP3481858A4 (he)
JP (3)	JP7755922B2 (he)
KR (2)	KR20190044617A (he)
CN (2)	CN119120484A (he)
AU (3)	AU2017293925C1 (he)
BR (1)	BR112019000182A2 (he)
IL (3)	IL311984A (he)
MX (3)	MX2019000175A (he)
SG (1)	SG11201900085TA (he)
WO (1)	WO2018009832A1 (he)
ZA (2)	ZA201900456B (he)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL311984A (he) *	2016-07-07	2024-06-01	Hughes Howard Med Inst	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש
US11713470B2 (en) *	2017-03-20	2023-08-01	University of Pittsburgh—of the Commonwealth System of Higher Education	Targeted gene therapies for pain and other neuro-related disorders
CN111556751B (zh) *	2017-11-10	2024-07-12	霍华休斯医学研究院	经修饰的配体门控的离子通道及使用方法
IL274702B2 (he)	2017-11-27	2026-04-01	Coda Biotherapeutics Inc	תרכובות ושיטות למחלות נוירולוגיות
KR102489109B1 (ko) *	2020-06-02	2023-01-16	부산대학교 산학협력단	아세틸콜린 수용체 변이 유전자를 유효성분으로 포함하는 근긴장 이상증 치료용 조성물
AU2021329529A1 (en) *	2020-08-21	2023-04-27	Trames Bio, Inc.	Compositions and methods for neurological diseases
WO2022255915A1 (en) *	2021-06-01	2022-12-08	Agneta Nordberg	Pet radiotracers
US20250145687A1 (en) *	2022-01-31	2025-05-08	Howard Hughes Medical Institute	Modified ligand-gated ion channels and methods of use
IL315059A (he) *	2022-02-18	2024-10-01	Trames Bio Inc	ערוצי יונים שנפתחים באמצעות ליגנדים ושיטות השימוש בהם
EP4514831A4 (en) *	2022-04-27	2026-06-17	Hughes Howard Med Inst	Chemogenetic receptors and their manufacturing and use processes
EP4702043A1 (en) *	2023-04-28	2026-03-04	Kriya Therapeutics, Inc.	Chimeric modified ion channels and uses thereof for treatment of trigeminal nerve disorders
CN116731008B (zh) *	2023-06-15	2025-10-24	西北大学	标记肺癌靶点烟碱型乙酰胆碱受体的免洗型荧光探针及制备方法
WO2025015092A1 (en)	2023-07-10	2025-01-16	Kriya Therapeutics, Inc.	Novel cam-kinase promoter and uses thereof for treating nervous system disorders
GB202401492D0 (en) *	2024-02-05	2024-03-20	Ucl Business Ltd	Chloride channels and uses thereof
WO2025249959A1 (ko) *	2024-05-30	2025-12-04	(주)메디톡스	융합단백질 및 이의 용도
WO2026117604A1 (en)	2024-11-27	2026-06-04	Kriya Therapeutics, Inc.	Compositions and methods for adeno-associated virus vector production

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6936457B1 (en)	1990-04-03	2005-08-30	Merck & Co., Inc.	DNA ENCODING HUMAN α AND β SUBUNITS OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR, CELLS TRANSFORMED THEREWITH, AND RECOMBINANT CELL LINE EXPRESSING A HUMAN α AND β SUBUNIT OF NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR
CZ20032814A3 (cs)	2001-04-20	2004-08-18	Pfizeráproductsáinc	Způsob přípravy �Ź@@substituovaných indenů a aryl@kondezovaných azapolycyklických sloučenin
GB0229586D0 (en)	2002-12-19	2003-01-22	Univ London Pharmacy	Novel tool for testing pharmacological actives
US20040204862A1 (en) *	2003-04-11	2004-10-14	Wainer Irving W.	Computer-based model for identification and characterization for non-competitive inhibitors of nicotinic acetylcholine receptors and related ligand-gated ion channel receptors
EP1699488A2 (en)	2003-12-23	2006-09-13	Pfizer Products Incorporated	Therapeutic combination for cognition enhancement and psychotic disorders
CN101044140A (zh) *	2004-04-22	2007-09-26	记忆药物公司	吲哚、1h－吲唑、1,2－苯并异噁唑和1,2－苯并异噻唑以及它们的制备和用途
DE602005024677D1 (de)	2004-04-22	2010-12-23	Memory Pharm Corp	Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
EP1993542A1 (en)	2006-03-01	2008-11-26	Galderma Research & Development, S.N.C.	Method of treating inflammatory skin diseases using tropisetron, and pharmaceutical compositions thereof
US8759504B2 (en)	2007-06-27	2014-06-24	Abbvie Inc.	Cholinergic/serotoninergic receptor and uses thereof
US20090123945A1 (en) *	2007-06-27	2009-05-14	Abbott Laboratories	Cholinergic/serotoninergic receptor and uses thereof
US9134307B2 (en)	2007-07-11	2015-09-15	X-Body, Inc.	Method for determining ion channel modulating properties of a test reagent
CL2008003507A1 (es)	2007-11-26	2009-11-27	Neuroderm Ltd	Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
WO2010042799A2 (en)	2008-10-09	2010-04-15	Howard Hughes Medical Institute	Novel chimeric ligand-gated ion channels and methods of use thereof
EP2459215A1 (en) *	2009-07-31	2012-06-06	Nabi Biopharmaceuticals	Method and kit for treating nicotine addiction
WO2011140279A1 (en)	2010-05-04	2011-11-10	Wayne State University	Aav-mediated subcellular targeting of heterologous rhodopsins in retinal ganglion cells
WO2015069752A1 (en) *	2013-11-05	2015-05-14	The Regents Of The University Of California	Acetylcholine binding protein ligands, cooperative nachr modulators and methods for making and using
EP3581580A1 (en)	2014-03-28	2019-12-18	The Board of Trustees of the Leland Stanford Junior University	Engineered light-activated anion channel proteins and methods of use thereof
US10435709B2 (en)	2014-12-04	2019-10-08	The Board Of Trustees Of The Leland Stanford Junior University	Dopamine receptor type 2 specific promoter and methods of use thereof
AU2016324317A1 (en)	2015-09-17	2018-03-08	Coda Biotherapeutics, Inc.	Compositions and methods for treating neurological disorders
IL311984A (he)	2016-07-07	2024-06-01	Hughes Howard Med Inst	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש
US11713470B2 (en)	2017-03-20	2023-08-01	University of Pittsburgh—of the Commonwealth System of Higher Education	Targeted gene therapies for pain and other neuro-related disorders
CN111556751B (zh)	2017-11-10	2024-07-12	霍华休斯医学研究院	经修饰的配体门控的离子通道及使用方法
MX2021009037A (es)	2019-01-30	2021-10-13	Diamond Therapeutics Inc	Composiciones y metodos para el manejo de trastornos.
US11878063B2 (en)	2019-03-05	2024-01-23	Children's Medical Center Corporation	Engineered ligands and uses thereof
JP7781052B2 (ja)	2019-08-21	2025-12-05	トレイムスバイオ，インコーポレイテッド	神経学的疾患のための組成物および方法
US20250145687A1 (en)	2022-01-31	2025-05-08	Howard Hughes Medical Institute	Modified ligand-gated ion channels and methods of use
EP4514831A4 (en)	2022-04-27	2026-06-17	Hughes Howard Med Inst	Chemogenetic receptors and their manufacturing and use processes

2017
- 2017-07-07 IL IL311984A patent/IL311984A/he unknown
- 2017-07-07 US US15/644,295 patent/US11084853B2/en active Active
- 2017-07-07 AU AU2017293925A patent/AU2017293925C1/en active Active
- 2017-07-07 BR BR112019000182-4A patent/BR112019000182A2/pt active Search and Examination
- 2017-07-07 JP JP2019520933A patent/JP7755922B2/ja active Active
- 2017-07-07 IL IL304040A patent/IL304040B2/he unknown
- 2017-07-07 CN CN202411225303.3A patent/CN119120484A/zh active Pending
- 2017-07-07 SG SG11201900085TA patent/SG11201900085TA/en unknown
- 2017-07-07 EP EP17824999.1A patent/EP3481858A4/en active Pending
- 2017-07-07 KR KR1020197003604A patent/KR20190044617A/ko not_active Ceased
- 2017-07-07 WO PCT/US2017/041147 patent/WO2018009832A1/en not_active Ceased
- 2017-07-07 IL IL264098A patent/IL264098B2/he unknown
- 2017-07-07 MX MX2019000175A patent/MX2019000175A/es unknown
- 2017-07-07 KR KR1020237033405A patent/KR102874080B1/ko active Active
- 2017-07-07 MX MX2025014724A patent/MX2025014724A/es unknown
- 2017-07-07 CN CN201780054322.6A patent/CN110023331B/zh active Active
2019
- 2019-01-07 MX MX2022013766A patent/MX2022013766A/es unknown
- 2019-01-22 ZA ZA2019/00456A patent/ZA201900456B/en unknown
- 2019-08-19 US US16/544,738 patent/US10981962B2/en active Active
2020
- 2020-05-06 US US16/868,205 patent/US11124554B2/en active Active
2021
- 2021-03-19 ZA ZA2021/01867A patent/ZA202101867B/en unknown
- 2021-08-09 US US17/397,658 patent/US12570705B2/en active Active
- 2021-09-08 US US17/468,907 patent/US12570706B2/en active Active
2022
- 2022-05-03 AU AU2022202948A patent/AU2022202948C1/en active Active
2023
- 2023-01-13 JP JP2023003807A patent/JP7538902B2/ja active Active
2024
- 2024-06-07 AU AU2024203888A patent/AU2024203888C1/en active Active
2025
- 2025-01-28 JP JP2025012015A patent/JP2025069252A/ja active Pending
2026
- 2026-02-04 US US19/529,937 patent/US20260159560A1/en active Pending

Also Published As

Publication number	Publication date
CN110023331B (zh)	2024-09-17
AU2017293925A1 (en)	2019-01-24
IL264098A (he)	2019-01-31
US12570705B2 (en)	2026-03-10
AU2022202948B2 (en)	2024-03-07
MX2022013766A (es)	2022-11-30
US20200377566A1 (en)	2020-12-03
IL304040B1 (he)	2024-05-01
KR102874080B1 (ko)	2025-10-23
US12570706B2 (en)	2026-03-10
MX2019000175A (es)	2020-01-20
IL304040B2 (he)	2024-09-01
CA3030147A1 (en)	2018-01-11
EP3481858A1 (en)	2019-05-15
AU2024203888C1 (en)	2026-05-21
CN110023331A (zh)	2019-07-16
WO2018009832A1 (en)	2018-01-11
JP7755922B2 (ja)	2025-10-17
NZ749744A (en)	2025-11-28
JP2023040251A (ja)	2023-03-22
IL264098B2 (he)	2023-12-01
US11124554B2 (en)	2021-09-21
ZA202101867B (en)	2022-08-31
EP3481858A4 (en)	2020-06-24
JP7538902B2 (ja)	2024-08-22
US11084853B2 (en)	2021-08-10
KR20190044617A (ko)	2019-04-30
US20180009862A1 (en)	2018-01-11
US20210403522A1 (en)	2021-12-30
IL264098B1 (he)	2023-08-01
US20220041671A1 (en)	2022-02-10
ZA201900456B (en)	2021-06-30
SG11201900085TA (en)	2019-02-27
IL304040A (he)	2023-08-01
KR20230145505A (ko)	2023-10-17
US10981962B2 (en)	2021-04-20
US20260159560A1 (en)	2026-06-11
JP2025069252A (ja)	2025-04-30
US20190375807A1 (en)	2019-12-12
AU2017293925C1 (en)	2025-02-27
AU2024203888A1 (en)	2024-06-27
JP2019530468A (ja)	2019-10-24
MX2025014724A (es)	2026-01-07
AU2022202948A1 (en)	2022-06-16
BR112019000182A2 (pt)	2019-04-16
CN119120484A (zh)	2024-12-13
AU2017293925B2 (en)	2022-02-03
AU2022202948C1 (en)	2024-09-26
AU2024203888B2 (en)	2025-12-18

Publication	Publication Date	Title
IL264098A (he)	2019-01-31	תעלות יונים מגודרות ליגנד שעברו שינוי ושיטות לשימוש
IL304117A (he)	2023-09-01	נוגדני אנטי–pvrig ושיטות לשימוש
IL292094A (he)	2022-06-01	ניואנטיגנים ושיטות לשימוש בהם
ZA202103620B (en)	2022-10-26	Modified ligand-gated ion channels and methods of use
IL282048A (he)	2021-05-31	אוקסיסטירולים ושיטות לשימוש בהם
PL3694529T3 (pl)	2024-12-16	Trójswoiste białka i sposoby zastosowania
PT3548033T (pt)	2024-08-09	Compostos e respectivos métodos de utilização
IL259747A (he)	2018-07-31	נוגדנים כנגד fcrl5 ושיטות לשימושם
BR112018000129A2 (pt)	2018-09-04	oxiesteróis e seus métodos de utilização
EP4212536C0 (en)	2025-02-19	BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
IL253463A0 (he)	2017-09-28	מתגי טרנסקריפציה מופעלי-קישור ושיטות שימוש בהם
IL251972B (he)	2022-03-01	ניתוח ושימוש בנופים
IL258768A (he)	2018-06-28	תרכובות הפועלות הדדית עם גליקאנים ושיטות שימוש
PL3353210T3 (pl)	2025-02-24	Przeciwciała anty-TIGIT i sposoby stosowania
PT3368534T (pt)	2021-03-09	Ditosilato de valbenazina e polimorfos do mesmo
BR112016024034A2 (pt)	2017-12-26	ativadores de canal iônico e métodos de uso
IL261653A (he)	2018-10-31	מוליקולות קושרות ilt7 ושיטות לשימוש בהן
IL250173B (he)	2022-01-01	מנגנון הפעלה ושיטות שימוש
IL313083A (he)	2024-07-01	תרכובות טרליפרסין ושיטות השימוש בהם
IL255749A (he)	2018-01-31	שילובים של אופיואידים ואצטילאמינים
IL260212B (he)	2021-08-31	רגולטורים של cftr ושיטות לשימוש בהם
DK3204428T3 (da)	2021-04-12	Nanokrystallinsk cellulose samt fremstilling og anvendelser af sådant nanokrystallinsk cellulose
PT3468603T (pt)	2022-07-21	Variantes do fec-gm e métodos de utilização
HK40009013A (en)	2020-06-19	Modified ligand-gated ion channels and methods of use